Skip to main content
Clinical Trials/NCT05543733
NCT05543733
Active, Not Recruiting
N/A

Home Exercise And Resiliency Training (HEART) Club: A Virtual Care at Home Program to Reduce Frailty for Adults With Fontan Circulation

University of Michigan1 site in 1 country53 target enrollmentMarch 1, 2023

Overview

Phase
N/A
Intervention
Home exercise program
Conditions
Fontan Physiology
Sponsor
University of Michigan
Enrollment
53
Locations
1
Primary Endpoint
Change in Frailty score by the Fried frailty instrument
Status
Active, Not Recruiting
Last Updated
24 days ago

Overview

Brief Summary

The purpose of this research study is to evaluate the impact of a telemedicine-based structured home exercise program on frailty and exercise capacity in individuals with Fontan heart physiology, demonstrate that a telemedicine exercise program reduces socioeconomic and geographic barriers to access to exercise training, and to explore the impact of a structured exercise program on markers of Fontan-associated liver disease.

Detailed Description

This study will require two in-person visits to the exercise physiology lab as well as virtual follow-up visits. Visit one will require participants to complete a cardiopulmonary exercise test (CPET), liver ultrasound, 6-minute walk, grip strength test, arm circumference measure, body composition analysis, anthropometrics measurement, surveys and a biomarker blood sample collection. The second in-person visit will require participants to complete a final cardiopulmonary exercise test, liver ultrasound, 6-minute walk, grip strength test and arm circumference, biomarker blood sample and final survey.

Registry
clinicaltrials.gov
Start Date
March 1, 2023
End Date
July 30, 2026
Last Updated
24 days ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Jesse Hansen

Assistant Professor of Pediatrics

University of Michigan

Eligibility Criteria

Inclusion Criteria

  • Males and females with Fontan physiology
  • 19 years old at age of enrollment

Exclusion Criteria

  • Height less than 130 centimeter (cm)
  • Pregnancy or the plan to become pregnant during the study period
  • Current intravenous inotropic drugs
  • Severe ventricular dysfunction assessed qualitatively by clinical echocardiography within six months prior to enrollment
  • Severe valvar regurgitation, ventricular outflow obstruction, or aortic arch obstruction assessed by clinical echocardiography within six months prior to enrollment
  • History of arrhythmia with exercise (excluding isolated supraventricular or ventricular ectopy without symptoms)
  • Inability to complete exercise testing at baseline screening
  • Noncardiac medical, psychiatric, and/or social disorder that would prevent successful completion of planned study testing or would invalidate its results

Arms & Interventions

Home exercise program

Intervention: Home exercise program

Outcomes

Primary Outcomes

Change in Frailty score by the Fried frailty instrument

Time Frame: day 1 (baseline), week 26 (final visit)

The questionnaire evaluates five components of the frailty syndrome (weakness, slowness, shrinkage, exhaustion, and diminished physical activity). Sum of the components will have a possible score of 0-5: not frail (score 0), pre-frail (score 1-2), frail (score great or equal to 3), undetermined (missing component).

Secondary Outcomes

  • Change in Patient-Reported Outcomes Measurement Information System (PROMIS) - 29(day 1 (baseline), week 26 (final visit))
  • Change in 6-minute walk distance(day 1 (baseline), week 26 (final visit))
  • Change in Aspartate Transferase (AST)(day 1 (baseline), week 26 (final visit))
  • Change in Alanine Aminotransferase (ALT)(day 1 (baseline), week 26 (final visit))
  • Change in platelets(day 1 (baseline), week 26 (final visit))
  • Change in 7-day average step count over 6 month period(Baseline, 6 months)
  • Change in peak oxygen consumption(day 1 (baseline), week 26 (final visit))
  • Change in alpha fetoprotein (AFP)(day 1 (baseline), week 26 (final visit))
  • Change in oxygen consumption at anaerobic threshold(day 1 (baseline), week 26 (final visit))
  • Change in Enhanced Liver Fibrosis (Elf) Score number(day 1 (baseline), week 26 (final visit))
  • Change in liver stiffness measured by ultrasound(day 1 (baseline), week 26 (final visit))
  • Change in Gamma-glutamyl Transferase (GGT)(day 1 (baseline), week 26 (final visit))

Study Sites (1)

Loading locations...

Similar Trials